Loading...
Potent combination antiretroviral therapy confers clinical benefits even when virologic suppression is not achieved, but one risk of such treatment is the accumulation of drug resistance mutations — and, hence, a reduction in future treatment options. Quantifying this risk, however, has been difficult.
To explore this issue further, investigators evaluated a subset of 110 patients from the EuroSIDA study who had two separate genotype resistance tests performed while remaining on a virologically failing regimen (viral loads >400 copies/mL). Drug resistance mutations were those defined by the International AIDS Society. Endpoints of interest were the accumulation of new mutations and the genotypic susceptibility score, which is calculated by c…